RVU — Ryvu Therapeutics SA Balance Sheet
0.000.00%
- PLN731.70m
- PLN616.30m
- PLN77.97m
Annual balance sheet for Ryvu Therapeutics SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 161 | 88.2 | 345 | 234 | 226 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 7.95 | 11.7 | 16.9 | 32.8 | 35.8 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 172 | 104 | 368 | 278 | 272 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 91.2 | 91.2 | 82.2 | 77.6 | 72.7 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 296 | 229 | 475 | 403 | 379 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 33.8 | 36.2 | 44.8 | 69.7 | 108 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 71.9 | 67.5 | 132 | 144 | 235 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 224 | 161 | 343 | 260 | 144 |
Total Liabilities & Shareholders' Equity | 296 | 229 | 475 | 403 | 379 |
Total Common Shares Outstanding |